对结直肠癌分子向治疗的研究进展
Shilin Huang1, Jiazhou Ye2, Xing Gao1
1Department of Digestive Oncology, Guangxi Medical University Cancer Hospital, Nanning, China.
Frontiers in pharmacology
|August 24, 2023
概括
大肠直肠癌 (CRC) 是一种常见的恶性瘤. 本综述详细介绍了转移性CRC (mCRC) 的向治疗方法,重点关注抗血管性,抗EGFR,BRAF和HER2药物,以改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 结肠直肠癌 (CRC) 代表着全球严重的健康负担,约占癌症发病率和死亡率的10%.
- 转移性结直肠癌 (mCRC) 是普遍存在的,有20%的患者被诊断为转移性疾病,而多达50%的患者后来发展为转移.
- 由于mCRC的复杂性涉及多种分子机制,因此需要针对性的治疗策略.
研究的目的:
- 审查目前针对各种结直肠癌途径的向药物.
- 突出针对性治疗的最新进展,包括抗血管性,抗表皮生长因子受体 (EGFR),BRAF和人类表皮生长因子受体2 (HER2) 剂.
- 强调了解癌症途径和原发性瘤位置如何影响治疗疗效.
主要方法:
- 对结直肠癌中向药物的文献综述.
- 专注于特定的向治疗类别的最新进展.
- 分析分子机制及其对治疗疗效的影响.
主要成果:
- 向药物改善了结直肠癌患者的生存率.
- 向治疗的有效性受到特定途径突变和原发性瘤位置的影响.
- 最近的进展包括新的抗血管原,抗EGFR,BRAF和HER2相关药物.
结论:
- 向疗法在结直肠癌的治疗中取得了重大进展.
- 基于分子分析的个性化治疗策略对于优化mCRC的结果至关重要.
- 对分子通路的持续研究将推动对结直肠癌更有效的向药物的开发.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


